VivoSeq
Neurology

Lennox-Gastaut Syndrome

12

Pipeline Programs↗

3

Active Trials↗

10

Companies Involved↗

Lennox-Gastaut syndrome is an emerging landscape with 12 programs across 10 companies. The most active players are Eisai, Lundbeck, Takeda. 3 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

40/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

71/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

2 programs

Phase 3Lundbeck logo

Lundbeck

2 programs

Phase 3Takeda logo

Takeda

1 program

Phase 3C

Catalyst Biosciences

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3N

Neurim Pharmaceuticals Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

26

clinical trials

Completed15 · 58%
Terminated4 · 15%
Withdrawn2 · 8%
Unknown status1 · 4%
Not yet recruiting1 · 4%
Available1 · 4%
Other2 · 8%

Clinical Trials

Trial Activity

26 trials

Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients With Lennox-Gastaut Syndrome
Recruiting·EEpygenix·Phase 3·NCT05066217·260 enrolled
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Active, not recruiting·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Approved·NCT05044819·154 enrolled
CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome
Not yet recruiting·—·Phase 1/2·NCT06738732·25 enrolled
Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
Completed·Eisai logoEisai·N/A·NCT02175173·707 enrolled
Clobazam in Patients With Lennox-Gastaut Syndrome
Completed·Lundbeck logoLundbeck·Phase 3·NCT00518713·238 enrolled
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
Completed·SSK Life Science, Inc.·Phase 1·NCT03731715·18 enrolled
An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes
Completed·GGW Research Ltd·Phase 3·NCT02224573·681 enrolled
A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)
Completed·Eisai logoEisai·Phase 3·NCT01146951·66 enrolled
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome
Completed·Lundbeck logoLundbeck·Phase 3·NCT01160770·267 enrolled
Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs
Completed·Eisai logoEisai·Phase 3·NCT01405053·37 enrolled
Clobazam in Subjects With Lennox-Gastaut Syndrome
Completed·Lundbeck logoLundbeck·Phase 2·NCT00162981·68 enrolled
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome
Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004776·10 enrolled
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
Completed·SSK Life Science, Inc.·Phase 1·NCT04062981·15 enrolled
A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome
Completed·Takeda logoTakeda·Phase 3·NCT04938427·270 enrolled
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 3·NCT02224690·171 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)